title: Gender difference regarding schizandrin pharmacokinetics in rats.
abstract: The difference in the pharmacokinetics of schizandrin (SZ) in male and female rats was studied. SZ concentrations in the plasma were determined after the intragastric (i.g) administration of 10 mg/kg and the intravenous (i.v) administration of 5 mg/kg in male and female rats, respectively. It was found that the plasma concentrations of SZ in female rats were significantly higher than those in male rats. Drug absolute bioavailability, based on the area under curve (AUC(0-tn)), in female rats was roughly 20 times of that in male rats. The terminate half-life (T(1/2)) in male rats was shorter than that in female rats. These results demonstrate the existence of marked gender differences for SZ in rats.
authors.affiliation: Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, Jiangsu, Peoples Republic of China.
authors.forename: Mei-Juan
authors.initials: MJ
authors.lastname: Xu
authors.forename: Guang-Ji
authors.initials: GJ
authors.lastname: Wang
authors.forename: Hai-Tang
authors.initials: HT
authors.lastname: Xie
authors.forename: Hao
authors.initials: H
authors.lastname: Li
authors.forename: Qing
authors.initials: Q
authors.lastname: Huang
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.forename: Yuan-Wei
authors.initials: YW
authors.lastname: Jia
authors.forename: Tian
authors.initials: T
authors.lastname: Lv
mesh_terms: D000818:Animals; D001682:Biological Availability; D034242:Cyclooctanes / Q000493:pharmacokinetics*; D003627:Data Interpretation, Statistical; D005260:Female; D006207:Half-Life; D007275:Injections, Intravenous; D007441:Intubation, Gastrointestinal; D017705:Lignans / Q000493:pharmacokinetics*; D008297:Male; D013058:Mass Spectrometry; D011083:Polycyclic Compounds / Q000493:pharmacokinetics*; D051381:Rats; D012727:Sex Characteristics
chemical_list: D034242:Cyclooctanes; D017705:Lignans; D011083:Polycyclic Compounds; C011105:schizandrin
references.citation: Yao Xue Xue Bao. 1983 Jul;18(7):491-5
references.pmid: 6659950
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Dec 15;828(1-2):55-61
references.pmid: 16236562
references.citation: Yao Xue Xue Bao. 2007 Jul;42(7):730-4
references.pmid: 17882956
references.citation: Eur J Drug Metab Pharmacokinet. 2005 Jan-Jun;30(1-2):69-73
references.pmid: 16010864
references.citation: Eur J Drug Metab Pharmacokinet. 2003 Apr-Jun;28(2):119-23
references.pmid: 12877569
references.citation: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1991 Feb;13(1):13-6
references.pmid: 1678991
references.citation: Drug Metab Dispos. 1996 Jan;24(1):28-33
references.pmid: 8825187
references.citation: Yao Xue Xue Bao. 1983 Jun;18(6):416-21
references.pmid: 6686408
references.citation: Chem Pharm Bull (Tokyo). 1979 Jun;27(6):1383-94
references.pmid: 544051